Zacks.com on MSN9h
GSK Meets Study Goal for Co-Administered RSV-Shingles VaccinesData from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving ...
Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get ...
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over ...
Shingles Doesn't Care is a catchphrase that comes from part of a 30-second TV commercial for SHINGRIX, which is a vaccine for ...
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...
The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback